Introduction: Chronic Obstructive Pulmonary Disease is a heterogeneous lung condition characterized by chronic respiratory symptoms due to abnormalities of the airways and/or alveoli that cause persistent, often progressive, airflow obstruction. The criterion for airflow obstruction, the FEV1/FVC ratio of < 0.70. CRP is a widely used clinical biomarker of inflammation and Fibrinogen has emerged as a promising biomarker in COPD. Aim of this study: To evaluate plasma CRP and Fibrinogen concentrations in COPD at baseline, during exacerbation and after one year follow up of the patients and to predict frequency of exacerbation, ICU admissions and mortality rate to improve outcomes of the disease. Patients and methods: This study was conducted as a prospective cohort study; 95 COPD patients were included in this study who attending the inpatient ward and outpatient clinic of Chest diseases Unit. Results: CRP is a significant predictor of frequency of exacerbations and at a cut-off value of > 17.5 and AUC of 0.658 with a sensitivity of 64% and specificity of 68% with PPV of 92.75% and NPV of 65.38%. While fibrinogen showed no significant value. There was a significant positive moderate correlation between CRP and frequency of exacerbations, CAT and ABCD. While there was a significant negative moderate correlation between FEV 1 and all two markers (Fibrinogen and CRP). Conclusion: Monitoring the two biomarkers Fibrinogen and CRP may help in the management and treatment of COPD by providing insights into the inflammatory status and disease severity in patients.

AECOPD, inflammatory markers, CAT scan, ICU admission.